LUIS ALBERTO PEREIRA DIAS
3 resultados
Resultados de Busca
Agora exibindo 1 - 3 de 3
Artigo IPEN-doc 29639 Development of glycan‑targeted nanoparticles as a novel therapeutic opportunity for gastric cancer treatment2023 - SANTOS, SOFIA N. dos; GUSHIKEN JUNIOR, DINO S.; PEREIRA, JHONATAS P.M.; IADOCICCO, NATALIA M.; SILVA, ANDRE H.; NASCIMENTO, TATIELLE do; DIAS, LUIS A.P.; SILVA, FLAVIA R. de O.; RICCI-JUNIOR, EDUARDO; SANTOS-OLIVEIRA, RALPH; BERNARDES, EMERSON S.Chemotherapy resistance remains a major cause of therapeutic failure in gastric cancer. The combination of genetic material such as interference RNAs (iRNAs) to silence cancer-associated genes with chemotherapeutics has become a novel approach for cancer treatment. However, finding the right target genes and developing non-toxic, highly selective nanocarrier systems remains a challenge. Here we developed a novel sialyl-Tn-targeted polylactic acid—didodecyldimethylammonium bromide nanoparticle (PLA-DDAB) nanoparticles (NPs) loaded with dsRNA targeting ST6GalNac-I and/or galectin-3 genes. Using single photon emission computed tomography (SPECT), we have demonstrated that 99mtechnetium radiolabeled sialyl-Tn-targeted nanoparticles can reach the tumor site and downregulate ST6GalNAc-I and galectin-3 RNA expression levels when injected intravenously. Furthermore, using an in vivo gastric tumor model, these nanoparticles increased the effectiveness of 5-FU in reducing tumor growth. Our findings indicate that cancer-associated glycan-targeted NPs loaded with dsRNA targeting ST6GalNAc-I and/or galectin-3 in combination with standard chemotherapy, have the potential to become a novel therapeutic tool for gastric cancer.Artigo IPEN-doc 28654 In vitro and in vivo response of PSMA-617 radiolabeled with CA and NCA lutetium-1772022 - BOAS, CRISTIAN A.W.V.; SILVA, JEFFERSON de J.; DIAS, LUIS A.P.; FREIRE, MARIA R.B.; BALIEIRO, LUIZA M.; SANTOS, CAROLINA S.F. dos; VIVALDINI, BIANCA F.; BENEDETTO, RAQUEL; VIEIRA, DANIEL P.; PASSOS, PRISCILA de Q.S.; MARUMO, MARIA H.; TEIXEIRA, LUIS F.S.; ARAUJO, ELAINE B. deThe PSMA-targeted radionuclide therapy has been explored since 2015 with radioisotope lutetium-177, whose β− emission range is adequate for micrometastases treatment. This radioisotope is obtained by two different production routes that directly affect the specific activity of lutetium-177 (non-carrier added and carrier added) and, consequently, the specific activity of radiopharmaceuticals, like 177Lu-PSMA-617. The influence of the specific activity of lutetium-177 on the properties of the radiopharmaceutical PSMA-617 was evaluated through pre-clinical studies. The in vitro study pointed to a lower constant of dissociation with non-carrier added lutetium-177 due to the difference in the specific activity. However, competition and internalization assays resulted in similar results for both lutetium-177. Based on these pre-clinical experiments, the total in vitro tumor cell binding and tumor uptake in vivo were similar, with no influence of the specific activity of the 177Lu-PSMA-617. Regardless the specific activity did not directly affect tumor uptake, the tumor/non-target organs ratios were higher for the radiopharmaceutical labeled with carrier added lutetium-177, which had the lowest specific activity.Artigo IPEN-doc 24857 Bovine serum albumin conjugated gold-198 nanoparticles as model to evaluate the damage caused by ionizing radiation to biomolecules2018 - SANTOS, JONNATAN J.; LEAL, JESSICA; DIAS, LUIS A.P.; TOMA, SERGIO H.; CORIO, PAOLA; GENEZINI, FREDERICO A.; KATTI, KATTESH V.; ARAKI, KOITI; LUGAO, ADEMAR B.Gold nanoparticles (AuNPs) have several applications including in medicine. Considering cancer as one of the most common diseases for men and women, new treatments and more specific and effective drugs, which cause less side effects, have been actively pursued. Among them, gold-198 can be engineered as theranostic agents, working as contrast (exploiting gamma emission) and treatment agents (beta emission). Accordingly, a new procedure for the production of 14 nm diameter radioactive citrate protected gold-198 nanoparticles, that were then conjugated with bovine serum albumin utilizing 3-mercaptopropionic acid directly bound to AuNPs surface as anchoring groups, generating fully dispersible nanoparticles in aqueous media, are described. The effect of gamma and beta radiation on grafted BSA was evaluated by direct irradiation of the corresponding cold material and comparing with the damage caused on BSA grafted gold-198 nanoparticles prepared from a neutron activated gold foil. The investigation by fluorescence and Raman spectroscopy indicated that the damage to BSA chromophore groups is proportional to the dose (from 0.1 to 1 kGy) and that chromophores groups close to the particle surface are more prone to damage. Gold-198 nanoparticles conjugated with bovine serum albumin showed that process is much more localized next to nanoparticles surface since each gold core acts as a punctual radiation source. In short, AuNPs can enhance the damage caused by irradiation of cold nanoparticles and AuNPs@MPA-BSA is a suitable model to probe the effect of gamma and beta emitter on biomolecules. Furthermore, the strategy of diluting the gold-198 with cold gold atoms was shown to be suitable to control the activity of 198AuNPs aiming medical applications, since the damage to BSA was found to be proportional to the relative concentration of gold-198.